Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy.

The document explores the cardiovascular complications associated with chimeric antigen receptor T-cell therapy in patients with multiple myeloma and lymphoma. The study, based on a retrospective cohort analysis, found that in-hospital cardiovascular events during CAR-T therapy were reversible and not linked to mortality, while post-discharge cardiovascular events were associated with increased mortality. The research highlights the importance of comprehensive cardiovascular assessment and management for patients undergoing CAR-T, emphasizing the need for further studies to optimize long-term outcomes. [Extracted from the article]